GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Better Therapeutics Inc (OTCPK:BTTX) » Definitions » Price-to-Tangible-Book

Better Therapeutics (Better Therapeutics) Price-to-Tangible-Book : (As of Jun. 09, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Better Therapeutics Price-to-Tangible-Book?

As of today (2024-06-09), Better Therapeutics's share price is $0.0096. Better Therapeutics's Tangible Book per Share of Sep. 2023 for the quarter that ended in Sep. 2023 was $-0.31. Hence, Better Therapeutics's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for Better Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

During the past 4 years, Better Therapeutics's highest Price to Tangible Book Ratio was 13.33. The lowest was 2.04. And the median was 3.09.

BTTX's Price-to-Tangible-Book is not ranked *
in the Biotechnology industry.
Industry Median: 2.77
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Better Therapeutics's share price is $0.0096. Better Therapeutics's Book Value per Sharefor the quarter that ended in Sep. 2023 was $-0.25. Hence, Better Therapeutics's P/B Ratio of today is .


Better Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Better Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Better Therapeutics Price-to-Tangible-Book Chart

Better Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Price-to-Tangible-Book
- - 3.47 -

Better Therapeutics Quarterly Data
Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.33 - - - -

Competitive Comparison of Better Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Better Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Better Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Better Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Better Therapeutics's Price-to-Tangible-Book falls into.



Better Therapeutics Price-to-Tangible-Book Calculation

Better Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Sep. 2023 )
=0.0096/-0.314
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Better Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Better Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Better Therapeutics (Better Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
548 Market Street, Suite 49404, San Francisco, CA, USA, 94104
Better Therapeutics Inc is a prescription digital therapeutics company developing a novel form of cognitive behavioural therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions.
Executives
Elder Granger director 5176 S. LEWISTON WAY, CENTENNIAL CO 80015
Mark A. Berman officer: Chief Medical Officer 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Geoffrey M. Parker director 15 RIORDAN PLACE, MENLO PARK CA 94025
Frank Karbe director, officer: See Remarks C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
David P Perry director, 10 percent owner, officer: See Remarks 1020 EAST MEADOW CIRCLE, PALO ALTO CA 94303
Andrew J. Armanino director C/O CALIFORNIA BANCORP, 1300 CLAY STREET, FIFTH FLOOR, OAKLAND CA 94612
Georgianna Maule-ffinch 2015 Trust 10 percent owner C/O BETTER THERAPEUTICS, INC., 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Mark Heinen officer: See Remarks 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Risa J Lavizzo-mourey director GE HEALTHCARE TECHNOLOGIES INC., 500 W. MONROE ST., CHICAGO IL 60661
Kevin J Appelbaum director, 10 percent owner, officer: Chief Executive Officer 4160 DUBLIN BLVD., SUITE 200, DUBLIN CA 94568
Suying Liu director 311 WEST 43RD STREET, 12TH FLOOR, NEW YORK NY 10036
Justin Zamirowski officer: Chief Commercial Officer 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Kristin Wynholds officer: Chief Product Officer 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Richard H Carmona director 1221 BROADWAY, OAKLAND CA 94612
David P. Perry 2015 Trust 10 percent owner 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104

Better Therapeutics (Better Therapeutics) Headlines